GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetron Holdings Ltd (NAS:GTH) » Definitions » Short Interest

Genetron Holdings (Genetron Holdings) Short Interest


View and export this data going back to 2020. Start your Free Trial

What is Genetron Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Genetron Holdings's Short Interest

For the Diagnostics & Research subindustry, Genetron Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetron Holdings's Short Interest Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetron Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Genetron Holdings's Short Interest falls into.



Genetron Holdings (Genetron Holdings) Business Description

Traded in Other Exchanges
N/A
Address
No. 8 Life Science Parkway, 1-2nd Floor, Building 11, Zone 1, Changping District, Beijing, CHN, 102206
Genetron Holdings Ltd is an oncology company in China. It is specialized in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The company's operating segment includes Diagnosis and monitoring - provision for LDT services; Diagnosis and monitoring - sale of IVD products and Development services. It generates maximum revenue from the Diagnosis and monitoring - provision for LDT services segment.